Redburn Atlantic Initiates Coverage On Tandem Diabetes Care with Buy Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Redburn Atlantic has initiated coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Buy rating and a price target of $60.
May 30, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Redburn Atlantic has initiated coverage on Tandem Diabetes Care with a Buy rating and a price target of $60, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $60 by Redburn Atlantic is likely to positively impact Tandem Diabetes Care's stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100